{"name":"Biodel","slug":"biodel","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-12-30","label":"Buprenorphine and naloxone Phase 3 readout (Opioid Use)","drug":"Buprenorphine and naloxone","drugSlug":"buprenorphine-and-naloxone","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":7,"colorKey":"immunology","drugs":[{"name":"Insulin VIAject™ (90%)","genericName":"Insulin VIAject™ (90%)","slug":"insulin-viaject-90","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"VIAject™","genericName":"VIAject™","slug":"viaject","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"Viaject 7","genericName":"Viaject 7","slug":"viaject-7","indication":"Diabetes treatment","status":"phase_3"},{"name":"BIOD-123","genericName":"BIOD-123","slug":"biod-123","indication":"Type 1 diabetes mellitus","status":"phase_2"},{"name":"Humalog Mix 75/25","genericName":"Humalog Mix 75/25","slug":"humalog-mix-75-25","indication":"Type 1 diabetes mellitus","status":"marketed"},{"name":"Insulin VIAject™ (75%)","genericName":"Insulin VIAject™ (75%)","slug":"insulin-viaject-75","indication":"Type 1 diabetes mellitus","status":"phase_3"},{"name":"recombinant human insulin","genericName":"recombinant human insulin","slug":"recombinant-human-insulin","indication":"Type 1 diabetes mellitus","status":"marketed"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"BEMA™","genericName":"BEMA™","slug":"bema","indication":"Opioid-induced breakthrough pain (primary development indication)","status":"phase_3"},{"name":"DFN-15 Active","genericName":"DFN-15 Active","slug":"dfn-15-active","indication":"Moderate to severe acute pain","status":"phase_3"},{"name":"EN3409","genericName":"EN3409","slug":"en3409","indication":"Moderate to severe chronic pain","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"Belbuca 600 µg","genericName":"Belbuca 600 µg","slug":"belbuca-600-g","indication":"Other","status":"phase_1"},{"name":"Buprenorphine and naloxone","genericName":"Buprenorphine and naloxone","slug":"buprenorphine-and-naloxone","indication":"Other","status":"discontinued"},{"name":"Oxycodone 60 mg","genericName":"Oxycodone 60 mg","slug":"oxycodone-60-mg","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"BEMA Fentanyl","genericName":"BEMA Fentanyl","slug":"bema-fentanyl","indication":"Breakthrough pain in opioid-tolerant cancer patients","status":"phase_3"}]}],"pipeline":[{"name":"BEMA™","genericName":"BEMA™","slug":"bema","phase":"phase_3","mechanism":"BEMA is a buccal film delivery system that rapidly dissolves in the mouth to deliver active pharmaceutical ingredients through the oral mucosa for faster systemic absorption.","indications":["Opioid-induced breakthrough pain (primary development indication)","Acute pain management"],"catalyst":""},{"name":"Insulin VIAject™ (90%)","genericName":"Insulin VIAject™ (90%)","slug":"insulin-viaject-90","phase":"phase_3","mechanism":"Insulin VIAject is a rapid-acting insulin formulation designed to achieve faster absorption and onset of action compared to standard insulin injections.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"VIAject™","genericName":"VIAject™","slug":"viaject","phase":"phase_3","mechanism":"VIAject is a rapid-acting insulin formulation that uses a proprietary excipient system to accelerate insulin absorption and onset of action.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Viaject 7","genericName":"Viaject 7","slug":"viaject-7","phase":"phase_3","mechanism":"Viaject 7 is a recombinant human insulin analog.","indications":["Diabetes treatment"],"catalyst":""},{"name":"BEMA Fentanyl","genericName":"BEMA Fentanyl","slug":"bema-fentanyl","phase":"phase_3","mechanism":"BEMA Fentanyl is a fentanyl formulation delivered via a buccal mucoadhesive patch that provides rapid opioid analgesia for breakthrough pain.","indications":["Breakthrough pain in opioid-tolerant cancer patients"],"catalyst":""},{"name":"BIOD-123","genericName":"BIOD-123","slug":"biod-123","phase":"phase_2","mechanism":"BIOD-123 is a rapid-acting insulin formulation designed to improve postprandial glucose control in diabetes patients.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Belbuca 600 µg","genericName":"Belbuca 600 µg","slug":"belbuca-600-g","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Buprenorphine and naloxone","genericName":"Buprenorphine and naloxone","slug":"buprenorphine-and-naloxone","phase":"discontinued","mechanism":"12.1 Mechanism of Action Buprenorphine and naloxone sublingual tablet contains buprenorphine and naloxone. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is an opioid antagonist and produces opioid withdrawal signs and symptoms in individuals physically dependent on full opioid agonists when administered parenterally.","indications":[],"catalyst":""},{"name":"DFN-15 Active","genericName":"DFN-15 Active","slug":"dfn-15-active","phase":"phase_3","mechanism":"DFN-15 is a buprenorphine sublingual tablet formulation designed to provide rapid onset and consistent opioid receptor agonism for pain management.","indications":["Moderate to severe acute pain"],"catalyst":""},{"name":"EN3409","genericName":"EN3409","slug":"en3409","phase":"phase_3","mechanism":"EN3409 is a buprenorphine formulation designed to provide sustained opioid receptor agonism with reduced abuse potential through a specialized delivery technology.","indications":["Moderate to severe chronic pain","Opioid use disorder (maintenance treatment)"],"catalyst":""},{"name":"Humalog Mix 75/25","genericName":"Humalog Mix 75/25","slug":"humalog-mix-75-25","phase":"marketed","mechanism":"Humalog Mix 75/25 is a combination insulin product that provides both rapid-acting and intermediate-acting insulin to control blood glucose levels in diabetes.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Insulin VIAject™ (75%)","genericName":"Insulin VIAject™ (75%)","slug":"insulin-viaject-75","phase":"phase_3","mechanism":"Insulin VIAject is a rapid-acting insulin formulation designed to be absorbed faster than standard insulin injections, allowing for quicker onset of action and better postprandial glucose control.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""},{"name":"Oxycodone 60 mg","genericName":"Oxycodone 60 mg","slug":"oxycodone-60-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"recombinant human insulin","genericName":"recombinant human insulin","slug":"recombinant-human-insulin","phase":"marketed","mechanism":"Recombinant human insulin binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.","indications":["Type 1 diabetes mellitus","Type 2 diabetes mellitus"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE13LVFoQ3Z2UTl1WEFRR1I3Vkxla3lwMFFTMXBZZ3cwbXBnbnVHQm01NllSaWU5eGVIQTl0ODBPMU5GVHZ1WDUzaldDWVVGUlFoMHd5WFlxajUweVJMcFpnWGpR?oc=5","date":"2026-03-02","type":"pipeline","source":"Fierce Pharma","summary":"Creating a Complete View of Dermatology Care to Strengthen Brand and Portfolio Decisions to Drive Competitive Advantage - Fierce Pharma","headline":"Creating a Complete View of Dermatology Care to Strengthen Brand and Portfolio Decisions to Drive Competitive Advantage","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPWjhxTThNV2M4WFpqVWdGWWhvV2dabm9aUU50dFFsYVFreFF4eVREWVNsbkw4YTlydkhRMGtfSnliRUY3Uk45OXZBRGxRRnFGQWt4Y05pTEgzeGRMenNLV3pneDdyMHpNcW5YR0dXYXhiV2wySFdCcG9iLXFhdE9IaDFOeFFrWG5KMnpFYjJHMWg4aDFlcHdhVHc5dWxCM3VrTlZPdjF4aE5RMktla3hqRkpqNTBTR09SNjZOYVY4WmdKa3FYMUt4Y2NOa1g?oc=5","date":"2022-07-01","type":"pipeline","source":"Life Science Leader","summary":"Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper - Life Science Leader","headline":"Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxOMVJIV0xUd25nTjQtbFB1TTVfQkVEMEdGekJDdU9PZjdOMnlJTVJOUjhDdjdPcUtNaFNVWGx5RkhBR0tKTHMxX2YwUzc1dFJYcTdpdU1QU21SOTR0Vl9lWE8zb2xkM0pUOUpGamNJUkJfUk8yT2pHT1dlMzc4TGhBUTVlU3ZqNHU3OEhZd1FWbEloVHc4MlBQVnNMYkI3Ym0yN2lnNXhBX2o?oc=5","date":"2016-05-25","type":"pipeline","source":"News-Times","summary":"Biodel to merge with Boston pharmaceutical company - News-Times","headline":"Biodel to merge with Boston pharmaceutical company - News","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOdFZJbVdIS0g4c3IyRVhtUGtRZHJwUFhDWTBmc0k3U19sdEhsX0ZONHU4UGNiWEZkT0VRVzBzS1RqZTQyLWExRXZNN2Zib3k4S1VvMmJnQ2JPZ3djZDV5OUdYU0p2UEY0dy03OE0ybUt0NkJIQk1xVXViS2J5d05rSGMwbmxzYWZ1Z1hSNzhfTEJkZWZsWmNJUjhR?oc=5","date":"2014-01-25","type":"pipeline","source":"News-Times","summary":"Entrepreneur builds pharma industry in city - News-Times","headline":"Entrepreneur builds pharma industry in city - News","sentiment":"neutral"}],"patents":[],"drugCount":14,"phaseCounts":{"phase_3":8,"phase_2":1,"phase_1":2,"discontinued":1,"marketed":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}